American Association for Cancer Research
10780432ccr182366-sup-205766_2_supp_5221988_pj9mhs.pdf (619.1 kB)

Supplemental Tables and Figures from Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs

Download (619.1 kB)
journal contribution
posted on 2023-03-31, 21:13 authored by Sara A. Hurvitz, Joyce O'Shaughnessy, Ginny Mason, Denise A. Yardley, Mohammad Jahanzeb, Adam Brufsky, Hope S. Rugo, Sandra M. Swain, Peter A. Kaufman, Debu Tripathy, Laura Chu, Haocheng Li, Vincent Antao, Melody Cobleigh

This file includes Supplemental Table 1, Supplemental Table 2, Supplemental Table 3, Supplemental Table 4, Supplemental Table 5, Supplemental Figure 1, Supplemental Figure 2, Supplemental Figure 3, Supplemental Figure 4, and Supplemental Figure 5.



Patients with HER2-positive metastatic breast cancer (MBC) with central nervous system (CNS) metastasis have a poor prognosis. We report treatments and outcomes in patients with HER2-positive MBC and CNS metastasis from the Systemic Therapies for HER2-positive Metastatic Breast Cancer Study (SystHERs). SystHERs (NCT01615068) was a prospective, U.S.-based, observational registry of patients with newly diagnosed HER2-positive MBC. Study endpoints included treatment patterns, clinical outcomes, and patient-reported outcomes (PRO). Among 977 eligible patients enrolled (2012–2016), CNS metastasis was observed in 87 (8.9%) at initial MBC diagnosis and 212 (21.7%) after diagnosis, and was not observed in 678 (69.4%) patients. White and younger patients, and those with recurrent MBC and hormone receptor–negative disease, had higher risk of CNS metastasis. Patients with CNS metastasis at diagnosis received first-line lapatinib more commonly (23.0% vs. 2.5%), and trastuzumab less commonly (70.1% vs. 92.8%), than patients without CNS metastasis at diagnosis. Risk of death was higher with CNS metastasis observed at or after diagnosis [median overall survival (OS) 30.2 and 38.3 months from MBC diagnosis, respectively] versus no CNS metastasis [median OS not estimable: HR 2.86; 95% confidence interval (CI), 2.05–4.00 and HR 1.94; 95% CI, 1.52–2.49]. Patients with versus without CNS metastasis at diagnosis had lower quality of life at enrollment. Despite advances in HER2-targeted treatments, patients with CNS metastasis continue to have a poor prognosis and impaired quality of life. Observation of CNS metastasis appears to influence HER2-targeted treatment choice.

Usage metrics

    Clinical Cancer Research



    Ref. manager